Edgewise Therapeutics (EWTX) News Today → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free EWTX Stock Alerts $17.68 +0.24 (+1.38%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 4:29 AM | americanbankingnews.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Short Interest UpdateMay 14 at 1:21 PM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Edgewise Therapeutics (EWTX) and Forte Biosciences (FBRX)May 12 at 6:03 AM | americanbankingnews.comEdgewise Therapeutics (NASDAQ:EWTX) Trading Down 6.1%May 10, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 6.1%Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 6.1%May 10, 2024 | finance.yahoo.comEdgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial ResultsMay 10, 2024 | businesswire.comEdgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024May 9, 2024 | investorplace.comEWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024May 9, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down to $20.89Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down to $20.89May 7, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Reaches New 1-Year High at $21.51Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 1-Year High at $21.51May 6, 2024 | businesswire.comEdgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)May 5, 2024 | americanbankingnews.comJoanne M. Donovan Sells 3,682 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) StockMay 5, 2024 | americanbankingnews.comBehrad Derakhshan Sells 1,718 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) StockMay 5, 2024 | americanbankingnews.comKevin Koch Sells 3,152 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) StockMay 5, 2024 | americanbankingnews.comJohn R. Moore Sells 1,956 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) StockMay 5, 2024 | americanbankingnews.comR Michael Carruthers Sells 2,157 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) StockMay 4, 2024 | insidertrades.comInsider Selling: Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Sells 1,718 Shares of StockMay 3, 2024 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Behrad Derakhshan Sells 1,718 SharesEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) insider Behrad Derakhshan sold 1,718 shares of the stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $18.91, for a total transaction of $32,487.38. Following the completion of the sale, the insider now directly owns 13,422 shares of the company's stock, valued at $253,810.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.May 1, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Sets New 1-Year High at $20.90Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 12-Month High at $20.90April 30, 2024 | marketbeat.comabrdn plc Makes New $1.65 Million Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)abrdn plc bought a new position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 150,418 shares of the company's stock, vApril 29, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Trading 6.3% Higher Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 6.3%April 23, 2024 | businesswire.comEdgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular DystrophiesApril 22, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Up After Analyst UpgradeEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Up on Analyst UpgradeApril 22, 2024 | marketbeat.comRoyal Bank of Canada Boosts Edgewise Therapeutics (NASDAQ:EWTX) Price Target to $32.00Royal Bank of Canada increased their price target on shares of Edgewise Therapeutics from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday.April 22, 2024 | seekingalpha.comJANX Janux Therapeutics, Inc.April 18, 2024 | marketbeat.comVontobel Holding Ltd. Makes New Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Vontobel Holding Ltd. acquired a new position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 327,801 shares of the company's stock, valued at approximately $3,586,000. Vontobel Holding Ltd.April 17, 2024 | investing.comEdgewise reports positive Becker trial results, plans discussionApril 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX) and Progyny (PGNY)April 17, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Given Buy Rating at Truist FinancialTruist Financial restated a "buy" rating and set a $25.00 price objective on shares of Edgewise Therapeutics in a research note on Wednesday.April 17, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 3.4%Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 3.4%April 16, 2024 | marketbeat.comEdgewise Therapeutics' (EWTX) Outperform Rating Reaffirmed at WedbushWedbush restated an "outperform" rating and issued a $26.00 price target on shares of Edgewise Therapeutics in a research report on Tuesday.April 15, 2024 | businesswire.comEdgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)April 15, 2024 | marketbeat.comShort Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Expands By 27.7%Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 5,720,000 shares, an increase of 27.7% from the March 15th total of 4,480,000 shares. Currently, 9.1% of the shares of the company are sold short. Based on an average daily volume of 1,010,000 shares, the short-interest ratio is presently 5.7 days.April 5, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Trading Up 4.2%Edgewise Therapeutics (NASDAQ:EWTX) Shares Up 4.2%April 4, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.6%Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.6%March 30, 2024 | marketbeat.comShort Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Decreases By 17.9%Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) was the target of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 4,480,000 shares, a decrease of 17.9% from the February 29th total of 5,460,000 shares. Based on an average trading volume of 1,050,000 shares, the days-to-cover ratio is presently 4.3 days. Currently, 7.1% of the company's shares are sold short.March 28, 2024 | businesswire.comEdgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific SessionMarch 27, 2024 | businesswire.comEdgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024March 18, 2024 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Sees Significant Increase in Short InterestEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) was the target of a large increase in short interest in February. As of February 29th, there was short interest totalling 5,460,000 shares, an increase of 6.4% from the February 14th total of 5,130,000 shares. Approximately 9.1% of the shares of the company are sold short. Based on an average daily trading volume, of 967,100 shares, the short-interest ratio is currently 5.6 days.March 18, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 5.8%Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 5.8%March 15, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Up 5.2%Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 5.2%March 7, 2024 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Coverage Initiated by Analysts at Piper SandlerPiper Sandler initiated coverage on Edgewise Therapeutics in a research report on Thursday. They set an "overweight" rating and a $48.00 price objective for the company.March 5, 2024 | finance.yahoo.comEdgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024March 3, 2024 | marketbeat.comFmr LLC Lowers Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Fmr LLC lessened its position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 13.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,402,847 shares of the company's stock after selling 954,642 sharesFebruary 28, 2024 | businesswire.comEdgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific ConferenceFebruary 26, 2024 | finance.yahoo.comWall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should KnowFebruary 25, 2024 | investing.comEdgewise Therapeutics earnings missed by $0.04, revenue was in line with estimatesFebruary 24, 2024 | msn.comEdgewise Therapeutics (EWTX) Price Target Increased by 8.00% to 27.54February 22, 2024 | benzinga.comEdgewise Therapeutics Stock (NASDAQ:EWTX), Short Interest ReportFebruary 22, 2024 | benzinga.comEdgewise Therapeutics: Q4 Earnings InsightsFebruary 22, 2024 | msn.comEdgewise Therapeutics Non-GAAP EPS of $0.47 Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. EWTX Media Mentions By Week EWTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EWTX News Sentiment▼0.590.55▲Average Medical News Sentiment EWTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EWTX Articles This Week▼112▲EWTX Articles Average Week Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Syndax Pharmaceuticals News Today Amneal Pharmaceuticals News Today NewAmsterdam Pharma News Today Galapagos News Today Amphastar Pharmaceuticals News Today Deciphera Pharmaceuticals News Today Agios Pharmaceuticals News Today Structure Therapeutics News Today Keros Therapeutics News Today Rocket Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EWTX) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperPharma Giant Makes Deal with a "Drug Smuggler"Behind the MarketsHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
